Bryan Haardt.

LOS ANGELES—Eyenuk, a global artificial intelligence (AI) digital health company and developer of applications for AI eye screening and AI predictive biomarkers, has announced the appointment of Bryan Haardt as chief executive officer. Haardt has more than 25 years of experience founding and leading health care technology enterprises, according to the announcement. Paul Praino, Eyenuk's interim CEO, will continue to serve as chief commercial officer, his role before taking the interim job, the company said.

"I'm deeply honored to join Eyenuk and lead the next phase of our journey to ensure timely diagnosis of vision-threatening and life-threatening diseases through the company's solutions," said Haardt.

Eyenuk's flagship EyeArt AI eye screening system is the only autonomous AI solution to be both FDA-cleared in the U.S. for the detection of diabetic retinopathy (DR) and CE-marked under the EU MDR for the detection of DR, as well as age-related macular degeneration and glaucomatous optic nerve damage, the company said. Providers across the U.S. and in 26 other countries have used the EyeArt AI system to screen more than 300,000 patients since 2020, according to the announcement.

 
 
"On behalf of the board of directors, we are excited to welcome Bryan and believe he is the ideal operating leader to shepherd Eyenuk into its next stage of commercial growth," said Eyenuk executive chairman Rob Binney. "Bryan's track record of execution and value creation as an entrepreneur, product innovator and executive leader will be invaluable as Eyenuk extends its leadership in autonomous screening of blinding eye diseases, as well as in the development of new lines of AI screening for additional diseases. The board of directors wishes to thank Paul for his leadership during our recent transition, and for his efforts to ensure a seamless transition of Bryan into the role of CEO," he said.

According to the announcement, Haardt most recently served as leader of digital therapeutics and prescription digital therapeutics for Boehringer Ingelheim, a global pharmaceutical company. Prior to that, he was general manager of Boehringer Ingelheim's Pawru, whose digital platform connects veterinary professionals and pet owners. Haardt is also the co-founder and former CEO of Decisio Health Inc., a health care IT company that delivers actionable information through digital solutions to improve health care outcomes.